Worth reading
75Important
Scored from 3 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-246
百万円（売上高の前年同四半期比）Wording
Definitive
How definitive the wording is.Results for this period
First quarter2024年4月1日〜2024年6月30日ConsolidatedJapanese GAAPNet Sales2,360¥ millionYear on year -9.5%
Operating profit-96¥ million
Ordinary income-56¥ million
Net income attributable to owners of the parent-41¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets13,991¥ million
of which net assets 11,212 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueFine Chemicals Business ¥979 million (YoY +0.1%), Flame Retardants Business ¥1,048 million (YoY -15.9%), Health Support Business ¥331 million (YoY -13.0%)
Segment profitFine Chemicals Business ¥166 million (YoY +6.1%), Flame Retardants Business ¥11 million (YoY -93.8%), Health Support Business ¥15 million (YoY -50.0%)
Outlook and shareholder returns
Revision to Earnings ForecastNo change
Factors Behind Changes in Business Performance
難燃剤事業における市場環境悪化の影響が前期から継続し、電子材料部材や家電製品等に使用される一部プラスチック用難燃剤の需要が減少。ヘルスサポート事業では固定化抗菌剤等の売上が減少。
Disclosure regarding the going concern assumption
Not applicable
Breakdown of extraordinary income (loss)Extraordinary income None / Extraordinary loss Loss on disposal of non-current assets ¥0 million
Depreciation and amortization¥115 million
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年6月30日 |
| Net Sales | ¥2,360 million (YoY -9.5%) |
| Operating profit | ¥-96 million |
| Ordinary income | ¥-56 million |
| Profit attributable to owners of the parent | ¥-41 million |
| Total assets | ¥13,991 million |
| Net assets | ¥11,212 million |
| Revision to Earnings Forecast | No change |
| Segment revenue | Fine Chemicals Business ¥979 million (YoY +0.1%), Flame Retardants Business ¥1,048 million (YoY -15.9%), Health Support Business ¥331 million (YoY -13.0%) |
| Segment profit | Fine Chemicals Business ¥166 million (YoY +6.1%), Flame Retardants Business ¥11 million (YoY -93.8%), Health Support Business ¥15 million (YoY -50.0%) |
| Depreciation and amortization | ¥115 million |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Loss on disposal of non-current assets ¥0 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Factors Behind Changes in Business Performance | 難燃剤事業における市場環境悪化の影響が前期から継続し、電子材料部材や家電製品等に使用される一部プラスチック用難燃剤の需要が減少。ヘルスサポート事業では固定化抗菌剤等の売上が減少。 |
Items this document does not state (21)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.難燃剤事業における市場環境悪化の影響が前期から継続したため。難燃剤需要の減少や、ヘルスサポート事業における固定化抗菌剤等の売上減少も挙げられている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.